LSBCF (LakeShore Biopharma Co) EV-to-EBIT: -5.11 (As of Jul. 08, 2026)


What is LakeShore Biopharma Co EV-to-EBIT?

LakeShore Biopharma Co LSBCF EV-to-EBIT is -5.11 as of Jul. 08, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, LakeShore Biopharma Co's Enterprise Value is $59.59 Mil. LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-11.66 Mil. Therefore, LakeShore Biopharma Co's EV-to-EBIT for today is -5.11.

The historical rank and industry rank for LakeShore Biopharma Co's EV-to-EBIT or its related term are showing as below:

LSBCF's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 14.69
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. LakeShore Biopharma Co's Enterprise Value for the quarter that ended in Mar. 2025 was $104.17 Mil. LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-11.66 Mil. LakeShore Biopharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -11.19%.

LakeShore Biopharma Co  (OTCPK:LSBCF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

LakeShore Biopharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-11.656/104.16915
=-11.19 %

LakeShore Biopharma Co's Enterprise Value for the quarter that ended in Mar. 2025 was $104.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-11.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co EV-to-EBIT Related Terms

LakeShore Biopharma Co EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co EV-to-EBIT Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
EV-to-EBIT
0.00 0.00 -10.17 -2.83 -8.86

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only -10.17 -5.12 -2.83 0.00 -8.86

LSBCF vs ACUT, PPCB, ENSC: EV-to-EBIT Comparison

For the Biotechnology subindustry, LakeShore Biopharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's EV-to-EBIT falls into.


LakeShore Biopharma Co EV-to-EBIT Calculation

LakeShore Biopharma Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=59.587/-11.656
=-5.11

LakeShore Biopharma Co's current Enterprise Value is $59.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. LakeShore Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-11.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of -5.11 mean?
LakeShore Biopharma Co (LSBCF) has a EV-to-EBIT of -5.11 as of Jul. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's EV-to-EBIT too high?
LakeShore Biopharma Co's current EV-to-EBIT is -5.11.
How does LakeShore Biopharma Co's EV-to-EBIT compare to ACUT and PPCB?
LakeShore Biopharma Co's EV-to-EBIT of -5.11 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 14.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.69, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on LakeShore Biopharma Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LakeShore Biopharma Co's current EV-to-EBIT is -5.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current EV-to-EBIT of -5.11. The current EV-to-EBIT is -5.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current EV-to-EBIT is -5.11 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.